AMENDMENTS TO THE CLAIMS

1-6. (Cancelled)

7. (Currently amended) A compound of the formula (I):



(I)

wherein X is hydroxy;

Y is $-C(=R^2)-R^3-R^4$ wherein R^2 is oxygen atom or sulfur atom, R^3 is oxygen atom, sulfur atom or $N-R^5$, R^4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and R^5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl or optionally substituted aralkyl, or R^4 and $N-R^5$ may be taken together to form optionally substituted non-aromatic heterocyclic group;

$-S(=O)_q-R^6-R^7$ wherein R^6 is oxygen atom or $N-R^7$, R^7 each is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and q is 1 or 2;

$-S(=O)_q-R^8$ wherein R^8 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and q is as defined above;

$-P(=O)(OR^9)_2$ wherein R^9 each is independently hydrogen or optionally substituted alkyl;

halogenated alkyl; or

optionally substituted heteroaryl;

Z is hydrogen or optionally substituted aralkyl;

Z^1 and Z^3 each is independently a bond, alkylene or alkenylene;

Z^2 is alkylene, a C2 to ~~C8~~C6 straight or branched ~~alkenyl~~alkenylene, -CH(OH)-, -S-, -SO-, $-SO_2-$, $-SO_2NR^{10}-$, $-NR^{10}SO_2-$, -O-, $-NR^{10}-$, $-NR^{10}CO-$, $-CONR^{10}-$, -C(=O)-O-, -O-C(=O)- or -CO-;

R^{10} is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl;

R^1 is optionally substituted branched alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted non-aromatic heterocyclic group, optionally substituted aryl or optionally substituted heteroaryl;

p is 1 to 2, provided that when p is 2, the groups of the formula: $-Z^1-Z^2-Z^3-R^1$ are different from each other;

ring (A) is optionally further substituted aromatic heterocycle; and

the group of the formula: -C(Z)=C(X)Y in the formula (I) substitutes at an atom adjacent to a hetero atom in ring (A), a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

8. (Previously Presented) The compound according to claim 7 wherein Y is optionally substituted heteroaryl; and wherein the group of the formula: -C(Z)=C(X)- in the formula (I) substitutes at an atom adjacent to a hetero atom in Y, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

9. (Currently Amended) The compound according to claim 7 wherein X is hydroxy;

Y is $-C(=R^2)-R^3-R^4$ wherein R^2 is oxygen atom, R^3 is oxygen atom or $N-R^5$, R^4 is

hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted aralkyl and R^5 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl or optionally substituted aralkyl, or R^4 and N-R^5 may be taken together to form optionally substituted non-aromatic heterocyclic group;
optionally substituted tetrazolyl; optionally substituted triazolyl; optionally substituted thiazolyl; optionally substituted isoxazolyl; optionally substituted pyrazinyl; optionally substituted imidazolyl; optionally substituted pyrimidinyl or optionally substituted pyridyl, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

10. (Previously Presented) The compound according to claim 7 wherein ring (A) is optionally further substituted aromatic heterocycle containing nitrogen atom, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

11. (Previously Presented) The compound according to claim 7 wherein ring (A) is optionally further substituted pyridine, optionally further substituted pyrazine, optionally further substituted pyrimidine, optionally further substituted oxazole, optionally further substituted thiadiazole, optionally further substituted quinoline, optionally further substituted isoquinoline, optionally further substituted purine, optionally further substituted benzoxazole or optionally further substituted benzimidazole, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

12. (Previously Presented) The compound according to claim 7 wherein Z^2 is alkylene or -O-, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

13. (Previously Presented) The compound according to claim 7 wherein Z^1 and Z^3 each is independently a bond or alkylene and R^1 is optionally substituted branched alkyl, optionally substituted cycloalkyl, optionally substituted non-aromatic heterocyclic group, optionally substituted aryl or optionally substituted heteroaryl, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

14. (Previously Presented) The compound according to claim 7 wherein Z^1 is a bond; Z^2 is alkylene or -O-; Z^3 is a bond or alkylene; and ring (A) is optionally further substituted pyridine, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof.

15-16. (Cancelled)

17. (Withdrawn) A pharmaceutical composition which comprises as an active ingredient the compound according to any one of claims 7 to 14, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

18. (Withdrawn) A pharmaceutical composition useful for an anti-viral agent which comprises as an active ingredient the compound according to any one of claims 7 to 14, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

19. (Withdrawn) A pharmaceutical composition useful for an anti-HIV agent which comprises as an active ingredient the compound according to any one of claims 7 to 14, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

20. (Withdrawn) A pharmaceutical composition having an integrase-inhibiting activity which comprises as an active ingredient the compound according to any one of claims 7 to 14, a tautomer of the compound, a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier or diluent.

21. (Withdrawn) An anti-HIV medical mixture which comprises a reverse transcriptase inhibitor and/or a protease inhibitor in addition to the compound according to claim 7.

22. (Withdrawn) The anti-HIV medical mixture according to claim 21 which enhances an anti-HIV activity of a reverse transcriptase inhibitor and/or a protease inhibitor.

23. (Withdrawn) A method for treating AIDS or AIDS-related complication which comprises administering an effective amount of the compound according to claim 7 to a patient in need thereof.

24. (Cancelled)